-
Ceruvia Lifesciences Begins Dosing Volunteers In Research On Non Hallucinogenic LSD Compound
Thursday, January 19, 2023 - 12:17pm | 351Read More...Clinical-stage psychedelics biopharma company Ceruvia Lifesciences has dosed the first participant in its Phase 1 trial on NYPRG-101, aka BOL-148, an LSD non-hallucinogenic analog with a clinical and experimental administration history that dates back to the 1950s. "Having invested...
-
FDA Green Lights Ceruvia's Phase 2 Psilocybin Trial Program For Obsessive-Compulsive Disorder Treatment
Wednesday, June 29, 2022 - 2:30pm | 337Read More...Clinical-stage biopharma company Ceruvia Lifesciences recently received FDA approval for its Investigational New Drug (IND) application for a Phase 2 clinical trial to determine the efficacy and safety of proprietary synthetic psilocybin (SYNP-101) in treating obsessive-compulsive...
-
Zero Cost, FDA CGMP Approved LSD For Qualified Researchers, Provided By Ceruvia Lifesciences
Tuesday, May 31, 2022 - 4:07pm | 300Read More...Ceruvia Lifesciences, a biopharmaceutical company, announced that it has produced the world's first LSD that meets stringent "Current Good Manufacturing Practices" (CGMP) standards required by the FDA for new drug approvals and is offering to supply it at no cost to...
